Daewoong Pharmaceutical, 197,630 Shares Net Bought by Individuals Over Last 5 Days... Stock Price at 108,500 KRW (-1.81%)

Daewoong Pharmaceutical is trading at 108,500 KRW as of 9:30 AM on the 8th, down 1.81% from the previous day. The trading volume is 157,504 shares, which is about 10.42% of the previous day's volume. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling drugs such as Urusa and Albis.

On July 8, researcher Lee Hyerin of KTB Investment & Securities stated, "1) Even if a reversal of the result is expected, it will take four months, 2) regardless of the lawsuit outcome, exports to Evolus have been significantly weaker than expected due to COVID-19, and 3) there is a high possibility that the lawsuit will be prolonged until the final judgment rather than being settled through an agreement between the two companies, so litigation costs are expected to continuously burden earnings. From now on, it seems necessary to focus on the stock price and R&D value changes of HanAll Bio, which have a high weight on earnings direction and corporate value," and set Daewoong Pharmaceutical’s target price at 120,000 KRW.

Over the past five days, individual investors have net purchased 197,630 shares of Daewoong Pharmaceutical, while foreigners and institutions have net sold 24,136 shares and 165,687 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.